Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi is the latest large drugmaker to place a bet on TL1A, one of the hottest targets in inflammatory bowel disease. The French pharma agreed to pay Teva…
France's Sanofi and Israel's Teva said on Wednesday they had signed a co-development and co-commercialization agreement worth up to $1.5 billion for Teva's…
Sanofi and Teva's duvakitug Phase 2b maintenance (week 44) data demonstrated clinically meaningful durable efficacy: ulcerative colitis clinical remission…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Sanofi and Teva entered a global co-development and co-commercialization collaboration for duvakitug (TEV'574 / TEV-48574), a then-Phase 2b anti-TL1A monoclonal antibody for IBD, announced October 4, 2023 (closed November 30, 2023). Teva received $500M upfront and is eligible for up to $1.0B in development/launch milestones, with equal cost/profit share in major markets and royalties elsewhere; Sanofi leads Phase 3 and commercializes in North America, Japan and most of the world while Teva commercializes in Europe, Israel and select markets. The bet has so far been validated: on December 17, 2024 the Phase 2b RELIEVE UCCD basket study met its primary endpoints in both ulcerative colitis (47.8% high-dose clinical remission vs 20.45% placebo at week 14) and Crohn's disease (47.8% high-dose endoscopic response vs 13.0% placebo), with the partners claiming best-in-class potential and a clean safety profile. Durable maintenance (week 44) data reported at ECCO 2025 and on February 17, 2026 reinforced the profile. Sanofi initiated the Phase 3 program in IBD in late 2025 (induction study NCT07184996 and maintenance study NCT07185009, both recruiting; induction actual start October 8, 2025).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Teva Pharmaceutical Industries Ltd. (this deal) | 2023 | $1.5B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2023 deals · Sanofi SA deals · Gastroenterology deals